AT&T, Texas Instruments and Enphase Energy fall premarket; Hasbro rises
Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $2.68 billion, has disclosed the approval of 2024 annual cash bonuses for its named executive officers, following the company’s performance for the year ended December 31, 2024. The company’s stock, currently trading at $25.03, has experienced significant pressure recently, declining over 10% in the past week according to InvestingPro data. This decision was made by the Board of Directors on March 7, 2025, and the bonuses were awarded at 100% of each executive’s target annual bonus.
The company had previously reported other compensation details for the year 2024 in the Summary Compensation Table within its prospectus, filed on January 31, 2025. However, at that time, the annual cash bonuses for the named executive officers were not determined and were thus omitted from the table. While the company maintains strong liquidity with a current ratio of 2.66, InvestingPro analysis indicates challenges ahead, with net income expected to decline this year.
The updated Summary Compensation Table now reflects the bonuses paid to each named executive officer for 2024. Christopher Whitten Bernard, President and Chief Executive Officer, received a bonus of $241,644, bringing his total compensation for the year to $5,969,222. Clive A. Meanwell, Executive Chairman and former CEO, was awarded a bonus of $59,836, with a total compensation of $1,859,617. Chief Financial Officer and Chief Business Officer Christopher Visioli received a bonus of $190,000, for a total of $3,039,019. Chief Scientific Officer Brian Hubbard, Ph.D., was awarded a bonus of $181,430, totaling $1,196,932 for the year. Former Chief Financial Officer Gbola Amusa, M.D., received a bonus of $133,336, with a total compensation of $1,752,153.
The bonuses reflect the company’s performance and adherence to its compensation policy. This information is based on a press release statement filed with the SEC and is intended to provide transparency to investors and stakeholders regarding the company’s financial decisions and governance. Despite current challenges, including an EBITDA of -$96.87 million in the last twelve months, Wall Street remains optimistic about Metsera’s prospects, with analysts maintaining a Strong Buy consensus. InvestingPro subscribers can access 6 additional key insights about MTSR’s financial health and growth prospects.
In other recent news, Metsera Inc has garnered significant attention with its initial public offering (IPO) debut on the Nasdaq Global Select Market, opening 42% higher than its initial offering price. The company offered 15,277,778 shares at $18.00 each, with shares opening at $25.50. In addition, Metsera has provided underwriters a 30-day option to purchase an additional 2,291,666 shares. Several prominent financial firms, including BofA Securities, Goldman Sachs, and Guggenheim Securities, are acting as joint bookrunners for the offering.
Cantor Fitzgerald has initiated coverage of Metsera with an Overweight rating, citing the company’s potential in the obesity drug market. They praised Metsera’s lead injectable GLP-1 drug, which has shown promising results in a Phase 2 obesity trial. BofA Securities also initiated coverage with a Buy rating and a $38 price target, noting Metsera’s strong position in the obesity market with its diverse portfolio of treatments. Guggenheim echoed this sentiment, setting a Buy rating with a $56 target, emphasizing the potential of Metsera’s innovative pipeline, particularly its ultra-long-acting NuSH analog. These developments highlight Metsera’s emerging role in the biotechnology industry, with several analysts pointing to the potential for substantial growth and market capture.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.